UY36218A - “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1” - Google Patents

“derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1”

Info

Publication number
UY36218A
UY36218A UY0001036218A UY36218A UY36218A UY 36218 A UY36218 A UY 36218A UY 0001036218 A UY0001036218 A UY 0001036218A UY 36218 A UY36218 A UY 36218A UY 36218 A UY36218 A UY 36218A
Authority
UY
Uruguay
Prior art keywords
oxides
compounds
positive
muscarinic
receiver
Prior art date
Application number
UY0001036218A
Other languages
English (en)
Inventor
O'neil Steven Victor
Garnsey Michelle Renee
Brodney Michael Aaron
Zhang Lei
Davoren Jennifer Elizabeth
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY36218A publication Critical patent/UY36218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona, en parte, compuestos de la Fórmula I:N-óxidos de estos y sales aceptables desde el punto de vista farmacéutico de los compuestos o de los N-óxidos; procesos para la preparación de tales compuestos, Nóxidos o sales, intermediarios utilizados en su preparación y composiciones que los contienen, y sus usos para tratar trastornos mediados por M1 (o asociados a M1) que incluyen, por ejemplo, enfermedad de Alzheimer, esquizofrenia (por ejemplo, sus síntomas cognitivos y negativos), dolor, adicción y trastorno del sueño
UY0001036218A 2014-07-18 2015-07-17 “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1” UY36218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462026087P 2014-07-18 2014-07-18
US201562142691P 2015-04-03 2015-04-03

Publications (1)

Publication Number Publication Date
UY36218A true UY36218A (es) 2016-02-29

Family

ID=53783784

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036218A UY36218A (es) 2014-07-18 2015-07-17 “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1”

Country Status (5)

Country Link
US (1) US20160016907A1 (es)
CA (1) CA2897469A1 (es)
TW (1) TW201613890A (es)
UY (1) UY36218A (es)
WO (1) WO2016009297A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214508B2 (en) 2014-06-13 2019-02-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2017143041A1 (en) 2016-02-16 2017-08-24 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
JP6860551B2 (ja) * 2016-03-11 2021-04-14 武田薬品工業株式会社 芳香環化合物
WO2018042362A1 (en) * 2016-09-02 2018-03-08 Suven Life Sciences Limited Muscarinic m1 receptor positive allosteric modulators
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
US11312713B2 (en) 2017-03-10 2022-04-26 Pfizer Inc. Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
HUE063823T2 (hu) 2017-06-20 2024-02-28 Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként
AU2018289939B2 (en) * 2017-06-20 2022-06-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA3078164C (en) * 2017-10-27 2022-11-15 Suven Life Sciences Limited Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
US11851406B2 (en) 2018-06-13 2023-12-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
CN113219094A (zh) * 2021-05-07 2021-08-06 湖北欣泽霏药业有限公司 一种盐酸托莫西汀口服溶液光学异构体的液相色谱检测法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR112012014180A2 (pt) * 2009-12-17 2015-09-15 Merck Sharp & Dohme composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
US8883850B2 (en) 2010-05-28 2014-11-11 Merck Sharp & Dohme Corp. Naphthalene carboxamide M1 receptor positive allosteric modulators
EP2624697B1 (en) 2010-10-04 2015-11-25 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
MY179412A (en) * 2012-12-07 2020-11-05 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists

Also Published As

Publication number Publication date
US20160016907A1 (en) 2016-01-21
CA2897469A1 (en) 2016-01-18
TW201613890A (en) 2016-04-16
WO2016009297A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
UY36218A (es) “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1”
ECSP18078877A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
UY35628A (es) ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?.
CL2016002661A1 (es) Compuestos derivados de isoindolin-1-ona, con actividad del receptor colinérgico muscarínico m1 del modulador alostérico positivo; composición farmacológica; útiles para el tratamiento del alzheimer, esquizofrenia, dolor, trastornos del sueño, demencia asociada al parkinson o demencia con cuerpos de lewy.
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
UY37311A (es) Derivados de 5,7-dihidro-pirrolo-piridina
DOP2016000290A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
ECSP18093944A (es) 1H-Pirazolo[4,3-b]piridinas como inhibidores de PDE1
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015002222A1 (es) Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos.
MX2016012451A (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina.
CO7280468A2 (es) Antagonistas del receptor de 5-ht3
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
UY37947A (es) Amidas de imidazopiridina sustituidas y su uso
DOP2016000289A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2019000027A1 (es) Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CL2016001744A1 (es) Compuestos derivados de 1-bencil-3-(4-(4-oxifenil)piperidin-1-il)pirrolidin-2-ona, ligandos para el receptor de nmda subtipo nr2b; composición farmacéutica; y su uso para el tratamiento de trastornos del sistema nervioso central
BR112016023991A2 (pt) ativadores de herg policíclicos
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
CL2016002518A1 (es) Combinación farmacéutica de 8-ciclopropil-3-[2-(3-fluorofenil)etil]-7,8-dihidro-3h-[1,3]oxazino[6,5-g][1,2,3] benzotriazina-4,9-diona y un inhibidor de acetilcolinesterasa; composición farmacéutica; y uso para el tratamiento de los trastornos cognitivos asociados con el envejecimiento cerebral y enfermedades neurodegenerativas.
CL2016002066A1 (es) Derivados de indolarilsulfonamida como antagonistas del receptor 5-ht6

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220629